TY  - JOUR
T1  - FLUOKSETİN VE DÜŞÜK DOZ TRAZODONUN BİRLİKTE KULLANIMIYLA OLASI SEROTONİN SENDROMU DÜŞÜNDÜREN VE NARANJO İLAÇ YAN ETKİSİ OLASILIĞI ÖLÇEĞİ İLE DEĞERLENDİRİLEN BİR OLGU
TT  - A CASE POSSIBLE SEROTONIN SYNDROME CASE CAUSED BY COMBINED USE OF FLUOXETINE AND LOW DOSE TRAZODONE AND ASSESSED BY THE NARANJO ADVERSE DRUG REACTION PROBABILITY SCALE
AU  - Aydın, Sare
AU  - Batmaz, Sedat
AU  - Sümbül, Orhan
AU  - Akpınar Aslan, Esma
PY  - 2023
DA  - September
Y2  - 2023
DO  - 10.17343/sdutfd.1210458
JF  - Medical Journal of Süleyman Demirel University
JO  - Med J SDU
PB  - Süleyman Demirel University
WT  - DergiPark
SN  - 1300-7416
SP  - 572
EP  - 577
VL  - 30
IS  - 3
LA  - tr
AB  - Serotonin sendromu serotonerjik ajan kullanımı sonrasındaoluşan serotonin reseptörlerinin aşırı uyarılmasısonucu gelişen nadir görülen fakat mortal seyredebilensendromdur. Klinik belirti ve bulgular kognitif,nöromüsküler ve otonomik alanda görülmektedir. Serotonerjiketkili bir veya daha fazla ajanın birlikte kullanılmasıbu sendroma neden olur. Klinik görünümü hafifşiddette olup gözden kaçabilen olgular olduğu gibihayatı tehdit eden, yoğun bakım ve mekanik ventilasyongerektiren şiddette de olabilmektedir. Bu yazıdafluoksetin tedavisine trazodon eklenmesi ve doz artırılmasısonrasında 24 saat içerisinde gelişen serotoninsendromu düşündüren bir vaka sunulmuştur.
KW  - Fluoksetin
KW  - Serotonin sendromu
KW  - Trazodon
N2  - Serotonin syndrome is a rare but life-threateningsyndrome that develops as a result of excessivestimulation of serotonin receptors after the use ofserotonergic agents. Clinical signs and symptomsare seen in the cognitive, neuromuscular andautonomic areas. Combination of one or more drugswith serotonergic effect causes this syndrome. Whilethere are cases with a mild clinical appearance thatcan be overlooked, they can also be life-threateningand require intensive care and mechanical ventilation.In this article, a case of serotonin syndrome, whichdeveloped within 24 hours after adding trazodone tofluoxetine treatment and increasing the dose, waspresented.
CR  - 1. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. International Journal of Tryptophan Research. 2019;12:1178646919873925.
CR  - 2. Özdemir S, Kocabaşoǧlu N. Serotonin Sendromuna Güncel Bir
Yaklaşım. Klinik Psikofarmakoloji Bulteni. 2007;17(4).
CR  - 3. Sternbach H. The serotonin syndrome. Am J Psychiatry.
1991;148(6):705-13.
CR  - 4. Dunkley E, Isbister G, Sibbritt D, Dawson A, Whyte I. The Hunter
Serotonin Toxicity Criteria: simple and accurate diagnostic
decision rules for serotonin toxicity. Qjm. 2003;96(9):635-42.
CR  - 5. Radomski J, Dursun S, Reveley M, Kutcher S. An exploratory
approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Medical hypotheses. 2000;55(3):218-24.
CR  - 6. Coleman JJ, Pontefract SK. Adverse drug reactions. Clinical
Medicine. 2016;16(5):481.
CR  - 7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts
E, et al. A method for estimating the probability of adverse
drug reactions. Clinical Pharmacology & Therapeutics.
1981;30(2):239-45.
CR  - 8. Karunatilake H, Buckley NA. Serotonin syndrome induced
by fluvoxamine and oxycodone. Annals of Pharmacotherapy.
2006;40(1):155-7.
CR  - 9. Ailawadhi S, Sung KW, Carlson L, Baer M. Serotonin syndrome
caused by interaction between citalopram and fentanyl.
Journal of clinical pharmacy and therapeutics. 2007;32(2):199-
202.
CR  - 10. Pan J-J, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. Annals of Pharmacotherapy. 2003;37(2):209-11.
CR  - 11. Inaguma D, Kitagawa W, Hayashi H, Kanoh T, Kurata K, Kumon S. Three cases of severe hyponatremia under taking selective serotonin reuptake inhibitor (SSRI). Nihon Jinzo Gakkai
Shi. 2000;42(8):644-8.
CR  - 12. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in
an inpatient unit. International journal of geriatric psychiatry.
2002;17(3):231-7.
CR  - 13. Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatric disease and treatment. 2017:161-75.
CR  - 14. Bartlett D. Drug-induced serotonin syndrome. Critical care nurse. 2017;37(1):49-54.
CR  - 15. Kan R, Endou M, Unno Y. A case of serotonin syndrome following minimum doses of sertraline. Seishin Shinkeigaku Zasshi=Psychiatria et Neurologia Japonica. 2009;111(9):1041-6.
CR  - 16. Gelener P, Gorgulu U, Kutlu G, Ucler S, Inan LE. Serotonin
syndrome due to duloxetine. Clinical Neuropharmacology.
2011;34(3):127-8.
CR  - 17. Öztürk N, Ezgi K, Sözeri-Varma G, Değirmenci E. Düşük doz
essitalopram ile serotonin sendromu. Journal of Mood Disorders. 2013;3(1):37-40.
CR  - 18. Stahl SM. Prescriber's guide: Antidepressants: Stahl's essential psychopharmacology: Cambridge University Press; 2017.
CR  - 19. George TP, Godleski LS. Possible serotonin syndrome
with trazodone addition to fluoxetine. Biological psychiatry.
1996;39(5):384-5.
CR  - 20. Rao R. Serotonin syndrome associated with trazodone. International journal of geriatric psychiatry. 1997;12(1):129-30.
CR  - 21. Reeves RR, Bullen JA. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 1995.
UR  - https://doi.org/10.17343/sdutfd.1210458
L1  - https://dergipark.org.tr/en/download/article-file/2795946
ER  -